EUCTR2009-017052-27-DE进行中（未招募）不适用
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers - Focetria Tx
Medizinische Hochschule Hannover0 个研究点开始时间: 2009年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Transplant Recipients
- •- Adult subjects 18-60 years of age who have undergone prior renal, cardiac, liver, lung, or bone marrow transplantation for any reason, more than 3 months prior to enrolment
- •- Patients able to visit the outpatient clinic with a life expectancy of at least one year
- •- Patients who receive any immunosuppressive treatment currently taken to prevent organ rejection
- •Healthy Adults:
- •- Adult subjects 18-60 years of age
- •- Healthy individuals as determined by medical history, physical assessment and clinical judgment of the investigator
- •- Within the same age category (+/- 5 years) than the incidental transplanted patient
- •Transplant Recipients and Healthy Adults:
- •- Individuals who are able to comply with all study procedures and are available for all clinic visits scheduled in the study
- •- Women of child-bearing potential (WOCBP) must have used an acceptable contraceptive method for at least 2 months prior to study entry until 3 weeks after last vaccination:
- •o Female of childbearing potential is defined as a post onset of menarche or pre-menopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 year earlier, or (3) total hysterectomy
- •o Acceptable birth control methods are defined as one or more of the following:
- •*Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring)
- •*Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse
- •*Intrauterine device (IUD)
- •*Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least six months prior to the subject’s study entry
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Individuals who received any vaccine within 30 days prior to study entry
- •- Individuals who received a H1N1 vaccination less than 6 months prior to the study
- •- Influenza diagnosed by a physician within 4 months prior to the study start
- •- Pregnant or lactating females
- •- History of an anaphylactic (i.e. life-threatening) reaction to any of the components of the vaccines, including egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)
- •- Subjects who are not able to comprehend and to follow all required study procedures for the whole period of the study
- •- History of or any current illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study
- •- Temperature is = 38 °C or oral temperature = 38.5 °C within 3 days of intended study vaccination
- •- Administration of parenteral immunoglobulin compound – including HBIg, blood products, and/or plasma derivatives within 6 months prior to Visit 1 or planned during the full length of the study
- •- HIV infection, as previously determined or reported
- •- History of progressive or severe neurological disorders (including Guillain-Barré syndrome and convulsions, but excluding febrile convulsions)
- •- Subjects participating in another clinical trial and / or receiving investigational drug
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers - Fluad TxEUCTR2010-022871-78-DEMedizinische Hochschule Hannover
未知
2 期
DNK-651-3JPRN-jRCT2080223664DENKA SEIKEN CO.,LTD.500
进行中（未招募）
不适用
A phase II, open, study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine when administered as a booster dose to children aged 16-20 months, previously primed with GSK Biologicals’ combined DSSITGDPa-HBV-IPV/Hib vaccine, containing diphtheria toxoid from the Statens Serum Institute (SSI) of Denmark and tetanus toxoid from GSK Biologicals’ Kft [GD] or with GSK Biologicals licensed DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) in the primary vaccination study DTPa-HBV-IPV-116 (106786). - DTPa-HBV-IPV-120 BST:116Booster immunisation of healthy toddlers in the second year of life against diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b.EUCTR2007-005343-16-FIGlaxoSmithKline Biologicals450
已完成
2 期
A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adultsJPRN-jRCT2071210086Inoguchi Akihiro80
进行中（未招募）
1 期
A phase II trial to assess the safety, immunological activity of Trovax plus Pemetrexed/ Cisplatin in patients with malignant pleural mesothelioma. - SKOPOS TrialEUCTR2010-023230-22-GBVelindre NHS Trust29